

**FOR IMMEDIATE RELEASE**

## **Carmel Pharma to Expand with Help from Ohio Tax Credit Authority Incentive**

COLUMBUS, OH (April 26, 2011) – Carmel Pharma has solidified its commitment to the state of Ohio by making an investment to grow their workforce and expand operations in the city of Worthington. For that planned initiative, the company will receive a 60 percent Job Creation tax credit for three years and a 30 percent tax credit incentive for the following three years. “We are very pleased that the State of Ohio has worked with us to create a plan that best suits the needs of our growing company,” said David Schneider, Carmel Pharma’s president. “Our goal has always been to expand and continue to develop in a community that has welcomed us with open arms and the Ohio Department of Development has worked diligently with us to design a plan moving forward that will best meet the company’s needs,” added Schneider.

Carmel Pharma will expand their existing facility in Worthington and create seventeen new positions as part of this initiative, greatly increasing their current operation. Carmel Pharma AB is a global corporation with its’ US corporate headquarters located in Columbus, Ohio. Carmel Pharma USA provides sales, marketing, clinical support and distribution services to customers throughout the US. This new initiative will allow the company to grow and expand to meet the increasing demand for the PhaSeal closed-system drug transfer device (CSTD).

### **About Carmel Pharma (the maker of the PhaSeal System)**

Carmel Pharma AB, headquartered in Gothenburg, Sweden, is the manufacturer of the PhaSeal System for the safe handling of hazardous drugs. In the United States, PhaSeal is distributed by an U.S. affiliate office, Carmel Pharma, Inc., located in Columbus, OH. The PhaSeal System has been in use in the U.S. since 1999 and implemented in more than 2000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children’s in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; Vanderbilt University Medical Center in Nashville, TN; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit [www.phaseal.com](http://www.phaseal.com) or email [info@carmelpharmausa.com](mailto:info@carmelpharmausa.com). To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today’s clinical thought leaders, please visit [www.carmelpharmausa.com/media](http://www.carmelpharmausa.com/media) or contact Cheryl Jacobs at 614-318-2622 or [cheryl.jacobs@carmelpharma.com](mailto:cheryl.jacobs@carmelpharma.com)